Paclitaxel News and Research

RSS
Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.
Scientists discover underlying mechanisms of nerve damage

Scientists discover underlying mechanisms of nerve damage

Newly developed implantable device can deliver chemotherapy drugs directly to pancreatic tumors

Newly developed implantable device can deliver chemotherapy drugs directly to pancreatic tumors

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Halozyme Therapeutics doses first patient in Halo-301 | Pancreatic study

Research unveils standard front-line treatment for advanced ovarian cancer

Research unveils standard front-line treatment for advanced ovarian cancer

Moffitt researchers develop novel therapeutic strategy to keep resistant cells in check

Moffitt researchers develop novel therapeutic strategy to keep resistant cells in check

MDI Biological Laboratory scientist identifies potential drug therapy to reverse peripheral nerve damage

MDI Biological Laboratory scientist identifies potential drug therapy to reverse peripheral nerve damage

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

QT Vascular reports initial results from first-in-human study of Chocolate Heart drug-coated balloon

QT Vascular reports initial results from first-in-human study of Chocolate Heart drug-coated balloon

Post-progression afatinib exposure boosts NSCLC outcomes

Post-progression afatinib exposure boosts NSCLC outcomes

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Palbociclib and paclitaxel combination shrinks tumors in patient with ER positive breast cancer

Palbociclib and paclitaxel combination shrinks tumors in patient with ER positive breast cancer

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Researchers pinpoint mechanisms that cause chemoresistance in ovarian cancer patients

Researchers pinpoint mechanisms that cause chemoresistance in ovarian cancer patients

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

Artificial intelligence may improve outcomes in breast cancer patients

Artificial intelligence may improve outcomes in breast cancer patients

Three drug-like compounds may offer better odds of survival to patients with prostate cancer, find SMU researchers

Three drug-like compounds may offer better odds of survival to patients with prostate cancer, find SMU researchers

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Molecular packaging enhances cancer drug’s effectiveness at destroying tumors

Molecular packaging enhances cancer drug’s effectiveness at destroying tumors